EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 592 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance MOST POPULAR Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After... February 16, 2022 Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... June 14, 2022 ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) February 7, 2019 Cancer in My Community: Striving to Lead People to Cancer Care... November 22, 2022 Load more HOT NEWS Arsenic Trioxide in Combination with All-Trans Retinoic Acid for the Treatment... After Lung Cancer Screening, Follow-Up Procedures May Be Riskier than Thought Qué saber al buscar información sobre el cáncer en línea: perspectiva... EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi
